New Directions in the Drug Treatment of Parkinson??s Disease
- 1 January 1996
- journal article
- review article
- Published by Springer Nature in Drugs & Aging
- Vol. 9 (3) , 169-184
- https://doi.org/10.2165/00002512-199609030-00003
Abstract
No abstract availableKeywords
This publication has 69 references indexed in Scilit:
- Acute Administration of Levodopa-Benserazide and Tolcapone, a COMT Inhibitor, in Parkinsonʼs DiseaseClinical Neuropharmacology, 1995
- A randomised controlled study comparing bromocriptine to which levodopa was later added, with levodopa alone in previously untreated patients with Parkinson's disease: a five year follow up.Journal of Neurology, Neurosurgery & Psychiatry, 1994
- Clinical Potential of Catechol-O-Methyltransferase (COMT) Inhibitors as Adjuvants in Parkinsonʼs DiseaseCNS Drugs, 1994
- Current Status of Dopamine Agonists in Parkinson??s Disease ManagementDrugs, 1993
- A pilot study of N-methyl-D-aspartate (NMDA) antagonist in Parkinson's disease.Journal of Neurology, Neurosurgery & Psychiatry, 1992
- The molecular pharmacology of L-deprenylEuropean Journal of Pharmacology: Molecular Pharmacology, 1992
- Pergolide can induce soluble Superoxide dismutase in rat striataJournal Of Neural Transmission-Parkinsons Disease and Dementia Section, 1992
- Selegiline and Parkinson??s DiseaseDrugs, 1990
- Clinical Trial of Madopar HBS in Parkinsonian Patients with Fluctuating Drug Response after Long-Term Levodopa TherapyEuropean Neurology, 1987
- Increased life expectancy resulting from addition of l-deprenyl to Madopar® treatment in Parkinson's disease: A longterm studyJournal Of Neural Transmission-Parkinsons Disease and Dementia Section, 1985